Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | BID | P55957 | 3/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.38 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.38 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.38 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27302612 | 0.98 | LIPG (0.47) | TDP1L3MBTL1LIPGALOX5PTGS2 | |
| SCHEMBL27613235 | 0.98 | LIPG (0.47) | TDP1L3MBTL1LIPGALOX5PTGS2 | |
| SCHEMBL27474780 | 0.98 | LIPG (0.47) | TDP1L3MBTL1LIPGALOX5PTGS2 | |
| Bromide SCHEMBL28986872 | 0.96 | LIPG (0.46) | TDP1L3MBTL1LIPGALOX5PTGS2 | |
| SCHEMBL22597437 | 0.94 | GRM5 (0.40) | TDP1L3MBTL1LIPGALOX5PTGS2 | |
| SCHEMBL461554 | 0.91 | TDP1 (0.50) | TDP1L3MBTL1LIPGALOX5PTGS2 | |
| SCHEMBL23768448 | 0.89 | TDP1 (0.49) | TDP1L3MBTL1LIPGALOX5PTGS2 | |
| SCHEMBL1425613 | 0.89 | TDP1 (0.49) | TDP1L3MBTL1LIPGALOX5PTGS2 | |
| Hydrogen Sulfide SCHEMBL28566437 | 0.89 | TDP1 (0.49) | TDP1L3MBTL1LIPGALOX5PTGS2 | |
| SCHEMBL29031761 | 0.89 | TDP1 (0.49) | TDP1L3MBTL1LIPGALOX5PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503465-B2 | Process for preparing [3-chloro-2-[3-[2-[1-(2-chloroacetyl)-4-piperidyl]thiazol-4-yl]-4,5-dihydroisoxazol-5-yl]phenyl] methanesulfonate | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| EP-4077321-B1 | PROCESS FOR PREPARING [3-CHLORO-2-[3-[2-[1-(2-CHLOROACETYL)-4-PIPERIDYL]THIAZOL-4-YL]-4,5-DIHYDROISOXAZOL-5-YL]PHENYL] METHANESULFONATE | BAYER AG (DE) | 2025-06-25 | — | — | EP | disclosed |
| CN-114829360-B | Process for preparing Fluoxapiprolin intermediates | 拜耳公司 | 2025-03-07 | — | — | CN | disclosed |
| WO-2024252982-A1 | FRAGRANCE COMPOSITION | 高砂香料工業株式会社 | 2024-12-12 | — | — | WO | disclosed |
| US-20230031599-A1 | PROCESS FOR PREPARING [3-CHLORO-2-[3-[2-[1-(2-CHLOROACETYL)-4-PIPERIDYL]THIAZOL-4-YL]-4,5-DIHYDROISOXAZOL-5-YL]PHENYL] METHANESULFONATE | BAYER AKTIENGESELLSCHAFT (DE) | 2023-02-02 | — | — | US | disclosed |
| EP-4077321-A1 | PROCESS FOR PREPARING [3-CHLORO-2-[3-[2-[1-(2-CHLOROACETYL)-4-PIPERIDYL]THIAZOL-4-YL]-4,5-DIHYDROISOXAZOL-5-YL]PHENYL] METHANESULFONATE | Bayer Aktiengesellschaft (DE) | 2022-10-26 | — | — | EP | disclosed |
| CN-114829360-A | Process for the preparation of [ 3-chloro-2- [3- [2- [1- (2-chloroacetyl) -4-piperidinyl ] thiazol-4-yl ] -4, 5-dihydroisoxazol-5-yl ] phenyl ] methanesulfonate | 拜耳公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2021122752-A1 | PROCESS FOR PREPARING [3-CHLORO-2-[3-[2-[1-(2-CHLOROACETYL)-4-PIPERIDYL]THIAZOL-4-YL]-4,5-DIHYDROISOXAZOL-5-YL]PHENYL] METHANESULFONATE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-24 | — | — | WO | disclosed |
| US-20200331910-A1 | Mammalian and Bacterial Nitric Oxide Synthase Inhibitors | UNIV NORTHWESTERN (US) | 2020-10-22 | — | — | US | disclosed |
| US-10759791-B2 | Mammalian and bacterial nitric oxide synthase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2020-09-01 | — | — | US | disclosed |
| US-9951014-B2 | Mammalian and bacterial nitric oxide synthase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170275278-A1 | Mammalian and Bacterial Nitric Oxide Synthase Inhibitors | NORTHWESTERN UNIVERSITY (US) | 2017-09-28 | — | — | US | disclosed |
| EP-3215497-A2 | MAMMALIAN AND BACTERIAL NITRIC OXIDE SYNTHASE INHIBITORS | Northwestern University (US) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016073623-A2 | MAMMALIAN AND BACTERIAL NITRIC OXIDE SYNTHASE INHIBITORS | NORTHWESTERN UNIVERSITY (US) | 2016-05-12 | — | — | WO | disclosed |
| US-20160122302-A1 | Mammalian and Bacterial Nitric Oxide Synthase Inhibitors | NORTHWESTERN UNIVERSITY | 2016-05-05 | — | — | US | disclosed |
| CN-103313977-B | 1- (heterocyclic carbonyl) piperidines | BAYER IP GMBH | 2015-06-03 | — | — | CN | disclosed |
| CN-103313977-A | 1- (heterocyclic carbonyl) piperidines | BAYER IP GMBH | 2013-09-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331910-A1 | Mammalian and Bacterial Nitric Oxide Synthase Inhibitors | NOS1, NOS2, NOS3 | TDP1 871/4885L3MBTL1 4498/4885LIPG 105/4885 |
| US-12503465-B2 | Process for preparing [3-chloro-2-[3-[2-[1-(2-chloroacetyl)-4-piperidyl]thiazol-4-yl]-4,5-dihydroisoxazol-5-yl]phenyl] methanesulfonate | CTPS2, DCPS, DHPS | TDP1 3863/4885L3MBTL1 3767/4885LIPG 4733/4885 |
| US-20230031599-A1 | PROCESS FOR PREPARING [3-CHLORO-2-[3-[2-[1-(2-CHLOROACETYL)-4-PIPERIDYL]THIAZOL-4-YL]-4,5-DIHYDROISOXAZOL-5-YL]PHENYL] METHANESULFONATE | CTPS2, DCPS, DHPS | TDP1 3863/4885L3MBTL1 3767/4885LIPG 4733/4885 |
| US-20160122302-A1 | Mammalian and Bacterial Nitric Oxide Synthase Inhibitors | NOS1, NOS2, NOS3 | TDP1 698/4885L3MBTL1 2265/4885LIPG 427/4885 |
| US-20170275278-A1 | Mammalian and Bacterial Nitric Oxide Synthase Inhibitors | NOS1, NOS2, NOS3 | TDP1 871/4885L3MBTL1 4498/4885LIPG 105/4885 |
| US-10759791-B2 | Mammalian and bacterial nitric oxide synthase inhibitors | NOS1, NOS2, NOS3 | TDP1 871/4885L3MBTL1 4498/4885LIPG 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.